A Nutlin-3-Boost Makes The Whole Temozolomide Practice So Exciting

Geriatr Gerontol Int 2014; ���: ���C���. ""Our aim was to clarify the association between type 2 diabetes and the risk of low muscle mass in older adults. In the present study, 414 adults aged 65 years or older (144 patients with type 2 diabetes and 270 control participants) were included. Body composition was measured by dual-energy X-ray absorptiometry. Low muscle mass was defined as the appendicular skeletal muscle mass/height2 (ASM/Ht2) or appendicular skeletal muscle mass/weight (ASM/Wt) of http://www.selleckchem.com/products/ABT-737.html prevalence of low muscle mass was consistently higher in older men with diabetes than those without diabetes defined by ASM/Ht2 (57.6% vs 41.5%, P?=?0.040), ASM/Wt (23.7% vs 12.3%, P?=?0.046) and TSM/Wt (49.2% vs 20.0%, P? http://www.selleck.cn/products/Methazolastone.html vs 20.0%, P?=?0.030), but not by ASM/Ht2 (7.1% vs 8.6%, P?=?0.685). The risk of low muscle mass was approximately two- to fourfold higher in older adults with type 2 diabetes, even after adjusting for age, body mass index, current smoking and other risk factors. In Korean older adults, type 2 diabetes is associated with low muscle mass. Geriatr Gerontol Int 2014; 14 (Suppl. 1): 115�C121. The industrialized countries, including Korea, are rapidly aging.[1, 2] Estimates by the World Health Organization suggest that there were 600 million people aged 60 years or older in the year 2000, and that this number will increase to 1.2 billion by the year 2025.[3] Aging results in a change of body composition, such as a progressive loss of muscle mass and gain of fat mass.[4] Sarcopenia is the age-related decline in muscle mass, and is associated with increased disability and mortality.[5-7] As muscle is not only responsible for physical strength, stamina and balance, but also metabolically active tissue, sarcopenia might affect quality of life, the need for supportive http://www.selleckchem.com/products/Nutlin-3.html services and contribute to the development of metabolic disorders.[5, 8-10] Although the International Working Group on Sarcopenia (IWGS) and the European Working Group on Sarcopenia in Older People (EWGSOP) included measurements of physical performance and/or muscle strength in defining sarcopenia, earlier definitions focused on measurements of low muscle mass only.[11] Within the existing literature, which defined sarcopenia by low muscle mass, the prevalence of sarcopenia in adults aged 60�C70 years is in the range of 5�C13%.